{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:21:33Z","timestamp":1773937293269,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40801-026-00539-9","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:38:53Z","timestamp":1773182333000},"page":"121-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program"],"prefix":"10.1007","volume":"13","author":[{"given":"Patrick J.","family":"Kiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"McGiffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1415-4345","authenticated-orcid":false,"given":"Michael A.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"Suppl","key":"539_CR1","volume":"23","author":"AP Venook","year":"2025","unstructured":"Venook AP. Updates in metastatic colorectal cancer. J Natl Compr Canc Netw. 2025;23(Suppl):e255017.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"539_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"539_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2022. 2022. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428. Accessed Sept 2025."},{"issue":"9863","key":"539_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X.","journal-title":"Lancet"},{"issue":"20","key":"539_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1414325.","journal-title":"N Engl J Med"},{"issue":"8","key":"539_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901.","journal-title":"J Clin Oncol"},{"issue":"9","key":"539_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol"},{"issue":"10","key":"539_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.23.01234","volume":"42","author":"T Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. J Clin Oncol. 2024;42(10):1001\u201312. https:\/\/doi.org\/10.1200\/JCO.23.01234.","journal-title":"J Clin Oncol"},{"issue":"1","key":"539_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11\u20139. https:\/\/doi.org\/10.1200\/JCO.19.02107.","journal-title":"J Clin Oncol"},{"issue":"1","key":"539_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.2019-0433","volume":"25","author":"MA Morse","year":"2020","unstructured":"Morse MA, Overman MJ, Hartman L, et al. Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. Oncologist. 2020;25(1):33\u201345. https:\/\/doi.org\/10.1634\/theoncologist.2019-0433.","journal-title":"Oncologist"},{"key":"539_CR11","doi-asserted-by":"publisher","unstructured":"Gatalica Z, Vranic S, Xiu J, et al. Can pembrolizumab or nivolumab be efficiently used against colorectal cancers with defective mismatch repair and high index of microsatellite instability? Biomark Cancer. 2021;13:1179299X211048637. https:\/\/doi.org\/10.1177\/1179299X211048637.","DOI":"10.1177\/1179299X211048637"},{"issue":"6","key":"539_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac065","volume":"6","author":"P Iyer","year":"2022","unstructured":"Iyer P, Deng M, Handorf EA, et al. Assessing oncologists\u2019 adoption of biomarker testing in metastatic colorectal cancer using real-world data. JNCI Cancer Spectr. 2022;6(6):pkac065. https:\/\/doi.org\/10.1093\/jncics\/pkac065.","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"539_CR13","doi-asserted-by":"publisher","first-page":"e1118","DOI":"10.1093\/oncolo\/oyad244","volume":"28","author":"MA Lewis","year":"2023","unstructured":"Lewis MA, Stansfield L, Kelton JM, Lieu CH. Biomarker testing trends in patients with metastatic colorectal cancer who live in rural areas and urban clusters in the US. Oncologist. 2023;28(11):e1118\u201322. https:\/\/doi.org\/10.1093\/oncolo\/oyad244.","journal-title":"Oncologist"},{"issue":"12","key":"539_CR14","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/14796694.2025.2504246","volume":"21","author":"K Desai","year":"2025","unstructured":"Desai K, Amonkar M, Jain R, et al. Biomarker testing, treatment patterns, and outcomes in previously treated pMMR or non\u2013MSI-H metastatic colorectal cancer patients. Future Oncol. 2025;21(12):1483\u201394. https:\/\/doi.org\/10.1080\/14796694.2025.2504246.","journal-title":"Future Oncol"},{"issue":"19","key":"539_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194828","volume":"14","author":"A Puccini","year":"2022","unstructured":"Puccini A, Seeber A, Berger MD. Biomarkers in metastatic colorectal cancer: status quo and future perspectives. Cancers (Basel). 2022;14(19):4828. https:\/\/doi.org\/10.3390\/cancers14194828.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"539_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/13696998.2018.1458617","volume":"21","author":"A Chawla","year":"2018","unstructured":"Chawla A, Peeples M, Li N, et al. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. J Med Econ. 2018;21(6):543\u201352. https:\/\/doi.org\/10.1080\/13696998.2018.1458617.","journal-title":"J Med Econ"},{"key":"539_CR17","doi-asserted-by":"publisher","unstructured":"The \u201cAll of Us\u201d Research Program Investigators. The \u201cAll of Us\u201d Research Program. N Engl J Med. 2019;381(7):668\u2013676. https:\/\/doi.org\/10.1056\/NEJMsr1809937.","DOI":"10.1056\/NEJMsr1809937"},{"key":"539_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00146","volume":"6","author":"JG Ronquillo","year":"2022","unstructured":"Ronquillo JG, Green A, Olorunsaiye CZ, et al. Precision medicine landscape of genomic testing for patients with cancer in the NIH All of Us database using informatics approaches. JCO Clin Cancer Inform. 2022;6:e2100146. https:\/\/doi.org\/10.1200\/CCI.21.00146.","journal-title":"JCO Clin Cancer Inform."},{"issue":"5","key":"539_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz060.","journal-title":"Ann Oncol"},{"issue":"32","key":"539_CR20","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1200\/JCO.2015.61.9569","volume":"33","author":"DA Goldstein","year":"2015","unstructured":"Goldstein DA, Ahmad BB, Chen Q, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3727\u201332.","journal-title":"J Clin Oncol"},{"issue":"4","key":"539_CR21","first-page":"e751","volume":"17","author":"SK Cho","year":"2018","unstructured":"Cho SK, Hay JW, Barzi A. Cost-effectiveness analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer in the United States. Clin Colorectal Cancer. 2018;17(4):e751\u201361.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"539_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/COC.0000000000000231","volume":"41","author":"V Shankaran","year":"2018","unstructured":"Shankaran V, Ortendahl JD, Purdum AG, et al. Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States. Am J Clin Oncol. 2018;41(1):65\u201372. https:\/\/doi.org\/10.1097\/COC.0000000000000231.","journal-title":"Am J Clin Oncol"},{"key":"539_CR23","unstructured":"Centers for Medicare & Medicaid Services (CMS). Physician Fee Schedule, CY 2023. 2023. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule. Accessed 25 Aug 2025."},{"key":"539_CR24","unstructured":"Centers for Medicare & Medicaid Services (CMS). Inpatient Prospective Payment System (IPPS) Final Rule, FY 2023. 2023. https:\/\/www.cms.gov\/medicare\/acute-inpatient-pps. Accessed 25 Aug 2025."},{"key":"539_CR25","unstructured":"Centers for Medicare & Medicaid Services (CMS). Clinical Laboratory Fee Schedule (CLFS), CY 2023. 2023. https:\/\/www.cms.gov\/medicare\/clinical-laboratory-fee-schedule. Accessed 25 Aug 2025."},{"key":"539_CR26","unstructured":"Centers for Medicare & Medicaid Services (CMS). Medicare Part B Drug Average Sales Price (ASP) Pricing Files, CY 2023. 2023. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price-asp-pricing-files. Accessed 25 Aug 2025."},{"key":"539_CR27","unstructured":"Centers for Medicare & Medicaid Services (CMS). Medicare Part D Drug Spending Dashboard & Data, CY 2023. 2023. https:\/\/www.cms.gov\/research-statistics-data-systems\/medicare-drug-spending. Accessed 25 Aug 2025."},{"issue":"4","key":"539_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","volume":"6","author":"AH Briggs","year":"1997","unstructured":"Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327\u201340. https:\/\/doi.org\/10.1002\/(SICI)1099-1050(199707)6:4%3c327::AID-HEC282%3e3.0.CO;2-W.","journal-title":"Health Econ"},{"issue":"12","key":"539_CR29","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421\u20136. https:\/\/doi.org\/10.1007\/s40273-018-0697-3.","journal-title":"Pharmacoeconomics"},{"key":"539_CR30","unstructured":"Institute for Clinical and Economic Review (ICER). Value assessment framework: 2024\u20132025 update. https:\/\/icer.org\/assessment\/methods. Accessed Jan 2025."},{"issue":"5","key":"539_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4097\/kja.19183","volume":"72","author":"J In","year":"2019","unstructured":"In J, Lee DK. Survival analysis: part II\u2014applied clinical data analysis. Korean J Anesthesiol. 2019;72(5):441\u201357. https:\/\/doi.org\/10.4097\/kja.19183.","journal-title":"Korean J Anesthesiol"},{"key":"539_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00155","volume":"3","author":"M Stewart","year":"2019","unstructured":"Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, et al. An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer. JCO Clin Cancer Inform. 2019;3:1\u201315. https:\/\/doi.org\/10.1200\/CCI.18.00155.","journal-title":"JCO Clin Cancer Inform"},{"issue":"9","key":"539_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.18553\/jmcp.2025.31.9.890","volume":"31","author":"R Mudumba","year":"2025","unstructured":"Mudumba R, Liu X, Davis I, Romley JA, Nieva JJ. Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase\u2013positive non-small cell lung cancer. J Manag Care Spec Pharm. 2025;31(9):890\u20139. https:\/\/doi.org\/10.18553\/jmcp.2025.31.9.890.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"539_CR34","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137. https:\/\/doi.org\/10.1056\/NEJMp1405158.","journal-title":"N Engl J Med"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36:509\u201322.","journal-title":"Pharmacoeconomics"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00539-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:40:15Z","timestamp":1773931215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00539-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"6 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.J.K. is an employee of Amgen Inc. and holds stock in the company. These affiliations are disclosed in the interest of transparency and do not alter the author's adherence to the journal's publication ethics. M.W.M, T.C.S., and M.A.P. declare that they have no financial conflicts of interest that could be perceived as influencing the work reported in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Purdue University (IRB-2024-389, approved on June 5, 2024). The study was determined to be exempt under Category 4 for secondary analysis of de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants by the NIH\n                      All of Us\n                      Research Program at the time of enrollment. This study used only de-identified data provided through the Researcher Workbench platform, and no additional consent was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"Conceptualization: PJK; Methodology: PJK, MAP; Formal analysis: PJK; Writing\u2014original draft preparation: PJK; Writing\u2014review and editing: all authors; Supervision: MAP. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The data that support the findings of this study are available from the NIH\n                      All of Us\n                      Research Program. Restrictions apply to the availability of these data, which were used under license for the current study and are accessible only through the\n                      All of Us\n                      Researcher Workbench following approval of a registered research project and completion of required data use agreements.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable. No custom software code was developed for this study beyond standard statistical analyses conducted using publicly available R packages.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}